OBJECTIVE: We investigated the associations of circulating C-reactive protein (CRP) and interleukin-6 (IL-6) with cancer risk. METHODS: We examined the associations of CRP and IL-6 with incident cancer in two prospective cohorts, the British Women's Heart and Health Study (4,286 women aged 60-80) and the Caerphilly Cohort (2,398 men aged 45-59) using Cox regression and pooled our findings with previous prospective studies' in fixed and random effects meta-analyses. RESULTS: CRP and IL-6 were associated with some incident cancers in our cohorts, but the numbers of cancer cases were small. In our meta-analyses elevated CRP was associated with an increased overall risk of cancer (random effects estimate (RE): 1.10, 95% CI: 1.02, 1.18) and lung cancer (RE: 1.32, 95% CI: 1.08, 1.61). Its associations with colorectal (RE: 1.09, 95% CI: 0.98, 1.21) and breast cancer risks (RE: 1.10, 95% CI: 0.97, 1.26) were weaker. CRP appeared unrelated to prostate cancer risk (RE: 1.00 0.88, 1.13). IL-6 was associated with increased lung and breast cancer risks and decreased prostate cancer risk, and was unrelated to colorectal cancer risk. CONCLUSIONS: Our findings suggest an etiological role for CRP and IL-6 in some cancers. Further large prospective and genetic studies would help to better understand this role.
OBJECTIVE: We investigated the associations of circulating C-reactive protein (CRP) and interleukin-6 (IL-6) with cancer risk. METHODS: We examined the associations of CRP and IL-6 with incident cancer in two prospective cohorts, the British Women's Heart and Health Study (4,286 women aged 60-80) and the Caerphilly Cohort (2,398 men aged 45-59) using Cox regression and pooled our findings with previous prospective studies' in fixed and random effects meta-analyses. RESULTS:CRP and IL-6 were associated with some incident cancers in our cohorts, but the numbers of cancer cases were small. In our meta-analyses elevated CRP was associated with an increased overall risk of cancer (random effects estimate (RE): 1.10, 95% CI: 1.02, 1.18) and lung cancer (RE: 1.32, 95% CI: 1.08, 1.61). Its associations with colorectal (RE: 1.09, 95% CI: 0.98, 1.21) and breast cancer risks (RE: 1.10, 95% CI: 0.97, 1.26) were weaker. CRP appeared unrelated to prostate cancer risk (RE: 1.00 0.88, 1.13). IL-6 was associated with increased lung and breast cancer risks and decreased prostate cancer risk, and was unrelated to colorectal cancer risk. CONCLUSIONS: Our findings suggest an etiological role for CRP and IL-6 in some cancers. Further large prospective and genetic studies would help to better understand this role.
Authors: Corinne E Joshu; Kostantinos K Tsilidis; Sarah B Peskoe; Francis M Giardiello; Paul J Dluzniewski; William G Nelson; Christine A Iacobuzio-Donahue; Elizabeth A Platz Journal: Cancer Causes Control Date: 2014-01-17 Impact factor: 2.506
Authors: Gang Wang; Ni Li; Sheng Chang; Bryan A Bassig; Lanwei Guo; Jiansong Ren; Kai Su; Fang Li; Shuohua Chen; Shouling Wu; Yuhuan Zou; Min Dai; Tongzhang Zheng; Jie He Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-12-09 Impact factor: 4.254
Authors: Mia M Gaudet; Alpa V Patel; Lauren R Teras; Juzhong Sun; Peter T Campbell; Victoria L Stevens; Eric J Jacobs; Susan M Gapstur Journal: Int J Mol Epidemiol Genet Date: 2013-09-12
Authors: Joshua Demb; Esther K Wei; Monika Izano; Stephen Kritchevsky; Helen Swede; Anne B Newman; Michael Shlipak; Tomi Akinyemiju; Steven Gregorich; Dejana Braithwaite Journal: J Geriatr Oncol Date: 2018-08-03 Impact factor: 3.599
Authors: Heather S McKay; Joseph B Margolick; Otoniel Martínez-Maza; Joseph Lopez; John Phair; Giovanna Rappocciolo; Thomas N Denny; Larry I Magpantay; Lisa P Jacobson; Jay H Bream Journal: Cytokine Date: 2016-12-09 Impact factor: 3.861